Skip to main content

Table 1 Cox regression univariate analysis of variables for overall survival in AML patients

From: Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation

Variables Whole-cohort AML Non-M3 AML CN-AML
HR (95% CI) P HR (95% CI) P HR (95% CI) P
SPAG1 expression 2.280 (1.562–3.327) 0.000 2.011 (1.366–2.962) 0.000 2.279 (1.283–4.047) 0.005
SPAG2/UAP1 expression 1.313 (0.908–1.897) 0.148 1.536 (1.052–2.241) 0.026 1.051 (0.614–1.798) 0.857
SPAG3/SPAG8 expression 0.901 (0.624–1.302) 0.578 1.021 (0.699–1.490) 0.914 0.801 (0.469–1.367) 0.416
SPAG4 expression 0.881 (0.610–1.273) 0.501 1.047 (0.718–1.527) 0.812 0.762 (0.442–1.315 0.329
SPAG5 expression 0.845 (0.584–1.223) 0.373 0.747 (0.509–1.096) 0.136 0.564 (0.319–0.998) 0.049
SPAG6 expression 1.504 (1.039–2.178) 0.031 1.359 (0.929–1.988) 0.114 0.990 (0.575–1.705) 0.971
SPAG7 expression 0.752 (0.519–1.089) 0.131 0.820 (0.560–1.202) 0.310 0.854 (0.498–1.467) 0.568
SPAG9 expression 0.986 (0.683–1.423) 0.939 0.906 (0.621–1.321) 0.607 1.176 (0.686–2.014) 0.556
SPAG10/MFGE8 expression 0.890 (0.616–1.287) 0.537 1.026 (0.703–1.498) 0.892 0.696 (0.406–1.193) 0.187
SPAG13/ITPRID2 expression 0.854 (0.591–1.234) 0.401 0.777 (0.532–1.134) 0.191 1.170 (0.683–2.004) 0.567
SPAG16 expression 1.427 (0.985–2.069) 0.060 1.257 (0.857–1.843) 0.242 1.320 (0.769–2.266) 0.314
SPAG17 expression 0.936 (0.648–1.351) 0.722 0.913 (0.626–1.332) 0.637 0.850 (0.498–1.453) 0.553
  1. AML: acute myeloid leukemia; CN-AML: cytogenetically normal AML; HR: hazard ratio; CI: confidence interval. The prognostic value of SPAG11A, SPAG11B, and SPAG16/SPAM1 expression was not determined because the three members were hardly expressed in AML patients